TABLE 2.
Laboratory Marker | Continuation Group
|
Switch Group
|
||||
---|---|---|---|---|---|---|
Entry | 8 Week Change | 24 Week Change | Entry | 8 Week Change | 24 Week Change | |
Vascular Markers | ||||||
Flow-mediated dilation, % | 3.82 (2.71) | −0.41 (2.15) | −0.67 (3.35) | 3.09 (2.36) | 1.17 (4.20) | −0.10 (3.26) |
Nitroglycerin-mediated dilation, %* | 17.46 (9.08) | 6.88 (9.42) | −0.15 (8.55) | 17.85 (8.46) | −3.02 (6.43) | −4.77 (8.95) |
Metabolic Markers | ||||||
HOMA-IR | 1.75 (1.31) | −0.04 (1.09) | 0.58 (1.18) | 1.67 (0.94) | 0.17 (1.48) | 0.60 (1.42) |
Serum total cholesterol, mg/dL*‡ | 156.87 (32.93) | 4.00 (16.86) | 1.08 (9.88) | 154.07 (36.67) | −12.2 (16.95) | −12.64 (19.61) |
Serum HDL-C, mg/dL | 42.27 (10.16) | 0.85 (6.62) | 0.15 (6.09) | 39.33 (11.64) | 0.13 (6.48) | 0.29 (6.06) |
Serum LDL-C, mg/dL* | 89.39 (28.93) | 6.08 (16.01) | −2.23 (15.13) | 90.61 (37.78) | −8.58 (17.14) | −8.65 (18.24) |
Serum triglycerides, mg/dL | 125 (64) | −13(36) | 16 (98) | 120 (77) | −19 (66) | −22 (25) |
Immunologic/inflammatory Markers | ||||||
Serum hsCRP, mg/L‡ | 2.55 (2.45) | 0.99 (6.13) | −0.66 (2.07) | 3.93 (3.95) | −0.84 (2.70) | −2.16 (2.20) |
Serum IL-6, pg/mL | 1.95 (1.42) | −0.34 (1.32) | −0.62 (1.10) | 1.47 (1.66) | 0.24 (1.32) | −0.10 (0.88) |
sCD14, ng/mL*‡ | 2441.15 (378.02) | −173.28 (321.51) | −112.54 (421.26) | 2443.2 (283.94) | −412.16 (288.84) | −458.14 (319.03) |
sCD163, ng/mL‡ | 575.80 (252.64) | −28.96 (60.04) | −32.26 (64.18) | 577.21 (183.58) | 15.24 (90.31) | 32.00 (63.57) |
Bone Homeostasis Markers | ||||||
Serum alkaline phosphatase, mg/dL‡ | 84.00 (23.15) | −7.58 (9.85) | −4.92 (8.2) | 78.47 (15.25) | −7.07 (7.47) | −12.46 (9.44) |
Serum parathyroid hormone, pg/mL | 62.41 (18.39) | 0.19 (19.04) | 11.45 (39.73) | 56.51 (27.70) | −5.76 (22.42) | −10.08 (25.64) |
Serum 25(OH)vitamin D, ng/mL | 18.35 (20.31) | −1.01 (6.70) | −0.58 (9.95) | 13.70 (12.86) | 5.28 (9.46) | 4.50 (12.52) |
Renal Function/Injury Markers | ||||||
Serum creatinine, mg/dL*§ | 0.91 (0.23) | −0.01 (0.06) | −0.02 (0.10) | 0.93 (0.16) | 0.06 (0.08) | 0.08 (0.08) |
Serum cystatin C, mg/L†§ | 0.80 (0.14) | −0.06 (0.07) | −0.03 (0.06) | 0.75 (0.11) | 0.07 (0.09) | 0.07 (0.1) |
Creatinine clearance, mL/min§ | 129.64 (41.61) | −2.00 (18.78) | 12.25 (23.29) | 130.93 (39.88) | −7.36 (14.37) | −11.69 (12.66) |
Estimated GFR (2009 CKD-EPI), mL/min/1.732‡ | 110.55 (23.73) | 0.51 (4.71) | 0.74 (9.40) | 111.15 (20.89) | −4.77 (9.80) | −8.67 (8.78) |
Estimated GFR (2012 CKD-EPI Cystatin), mL/min/1.732†§ | 110.40 (17.13) | 6.86 (11.54) | 3.06 (8.07) | 115.79 (12.11) | −8.43 (11.26) | −8.50 (11.04) |
Estimated GFR (2012 CKD-EPI Cystatin-Creatinine), mL/min/1.732†§ | 100.19 (20.38) | 5.24 (7.15) | 2.72 (6.48) | 102.7 (16.78) | −7.09 (9.22) | −8.22 (6.70) |
Urine albumin/creatinine, mg/g | 7.32 (7.39) | 0.86 (8.13) | −1.57 (2.90) | 4.84 (3.98) | −1.51 (2.26) | 11.99 (44.84) |
Urine protein/creatinine, g/g | 0.12 (0.07) | −0.01 (0.02) | −0.01 (0.03) | 0.08 (0.05) | −0.01 (0.02) | 0.01 (0.04) |
Data presented as mean (standard deviation)
HOMA-IR, homeostasis model assessment-insulin resistance; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; hsCRP, high sensitivity C-reactive protein; IL-6, interleukin-6; sCD14 and 163, soluble cluster of differentiation 14 and 163; GFR, glomerular filtration rate
P<0.05 for differences between groups in the change from Entry to Week 8
P<0.01 for differences between groups in the change from Entry to Week 8
P<0.05 for differences between groups in the change from Entry to Week 24
P<0.01 for differences between groups in the change from Entry to Week 24